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1. Introduction 
The economic burden, albeit low quality of life of people in sub-Saharan Africa with non-
sexually transmitted recurrent urogenital tract infections is not the desired state of health. 
Associations exist between abnormal vaginal/penile microbiota and HIV. Excluding 
sexually transmitted diseases, microorganisms that originate from the gastrointestinal tract 
cause almost all infections of the vagina and bladder. There is a strong correlation between 
presence of the normal microbiota, particularly lactobacilli in the vagina with health, and an 
absence of these microorganisms in patients with urogenital infections. Disruption of the 
normal vaginal microbiota is caused by the use of broad-spectrum antibiotics, spermicides, 
hormones, dietary substances and factors not, as yet, fully understood. There is increasing 
body of evidence that probiotic microorganisms delivered in food such as yogurt or milk 
based foods and capsular preparations do have a role in preventing urogenital tract 
infections and in ameliorating diarrhea [Walker et al., 2006]. 
The use of probiotics defined as “live microorganisms which when administered in 
adequate amounts, confer health benefits on the host” (WHO/FAO, 2001), for the 
maintenance of health is already in use in developed countries. Probiotics are yet to be 
adopted in sub-Saharan Africa by health care providers. There are clinical evidence to show 
that probiotics can play a significant role in resolving diarrhea, boost immune system and 
prevent recurrent urogenital infections including bacterial vaginosis, which is a risk factor in 
HIV acquisition. The aim of this chapter is to highlight the burden of urogenital infections in 
Africa, impact of abnormal vaginal microbiota, clinical evidence on the use of probiotics for 
urogenital health care and last but not the least, the rationale for suggesting the use of 
probiotics in the management of HIV infection in sub-Saharan Africa. 
2. Burden of urogenital infections in Africa 
Non-sexually transmitted urogenital infections such as bacterial vaginosis (BV), yeast 
vaginitis, urinary tract infections (UTI) afflict more than one billion women around the 
world annually [Hay, 2000]. However, it is worthwhile to briefly explain what BV is. 
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BV is a syndrome defined by symptoms and signs of a white, homogenous, malodorous 
discharge, vaginal itching, increase in vaginal pH above 4.5, development of a fishy odor when 
10% KOH reacts with an altered organic acid pattern (including increases in putrescine, 
cadaverine, and trimethylamine), and vaginal epithelial cells observed on wet mount spotted 
with adherent small rods or cocci (“clue cells”). Three of 4 (discharge, pH, odor, clue cells) 
clinical or laboratory signs are required for BV diagnosis by the Amsel criteria [Amsel et al., 
1983]. The relative changes in bacterial concentrations have been tracked by Nugent scoring, 
which uses staining and microscopy to grade the predominance of 3 morphotypes: lactobacilli, 
small gram-variable rods or Gram-negative rods (G. vaginalis, Bacteroides), and curved gram-
variable rods [Nugent et al 1991]. Currently, molecular techniques are providing new ways to 
categorize the change in composition of the vaginal microbiota [Verhelst et al 2005]. The 
predominance of G. vaginalis, Bacteroides spp., and A. vaginae in BV is also accompanied by 
increases in other anaerobes, such as prevotella, mobiluncus, genital mycoplasmas, and an 
unfolding community of unculturable bacteria but not necessarily a decrease in the geometric 
mean concentration of lactobacilli [Fredricks et al 2007] 
Although the estimate for non-sexually transmitted urogenital infections in women in sub-
Saharan Africa is difficult to get, but statistics may be grim due to the rising trend in 
HIV/AIDS in the region. The infection process is not a hygiene issue. Anatomically, the 
proximity of the vagina and the anus predisposes women to these infections. Most cases of 
BV, UTI, and yeast vaginitis arise from the host's gastrointestinal tract, as microbes ascend 4 
to 5 cm from the anus, thereby showing that the intestine and urogenital tracts are 
‘connected’ and that intestinal health can influence the vagina and bladder. The process is 
mediated by bacterial adherence and is not altered by antibiotic use. Studies have shown 
that the host’s cells remain susceptible to pathogen adhesion before, during and after 
antibiotic administrations [Reid et al 1988]. Since the discovery of the ‘magic bullet’, the 
therapeutic approaches to treatment and prevention of urogenital infections in Africa and in 
the rest of the world have remained constant for more than half of a century. Antibiotics and 
antifungals still remain the armaments of therapy, despite their well-known side effects 
chronicled in Pharmaceutical compendia, ranging from super infections, diarrhea, 
depression, to renal failure. The emergence of ‘superbugs’ as a result of antimicrobial 
resistance is not only an economic burden to the health sector, but also constitute a treat to 
the survival of the human species.  
The burden of urogenital infections is becoming more worrisome in that most women are 
not aware that they have particularly, bacterial vaginosis. Klebanoff et al [2004], recently 
revealed that women not detecting odor or discharge do not realize that their vaginal 
microbiota is abnormal and a 14.2% prevalence of BV have been found in healthy Nigerian 
women [Anukam et al 2006]. Consequently the quality of life of the women with these acute 
and chronic infections has been found to be adversely affected significantly [Ellis &Verma, 
2000). There is an association between BV and preterm delivery [Hay, 1994] and also 
between BV and early spontaneous miscarriage prior to 16 weeks gestation [Oakeshott et al., 
2002]. Associations between BV and urinary tract infections (UTI) [Hillebrand et al., 2002] as 
well as between BV and history of infertility caused by tubal factors [Wilson et al., 2002] 
have been reported in other studies. There is also an association between smoking and BV 
(Smart et al., 2004). 
A previous longitudinal study of women in the United Kingdom showed that at any given 
time during the menstrual cycle, the vaginal microbiota may be "abnormal" [Keane et al 
1997]. When symptoms of pain, discharge, and itching occur, many women diagnose these 
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symptoms as yeast infections and self-treat with over-the-counter antifungals, when in fact 
they have BV. This misdiagnosis and mistreatment can result in adverse consequences 
[Ferris et al 1996]. Antimicrobial treatment for BV is suboptimal, with some cure rates as low 
as 60% 1 month after treatment, and subsequent overgrowth of pathogenic bacteria in the 
vagina often occurs [Livengood et al 1999]. 
3. Abnormal vaginal/penile microbiota and HIV 
Studies have found a significant association between BV and human immunodeficiency 
virus (HIV) infection (Sewankambo et al., 1997). In a prospective study of Kenyan sex 
workers, the absence of lactobacilli in vaginal cultures was associated with a 2.0-fold 
increase in HIV acquisition and a 1.7-fold greater risk of developing gonorrhea (Martin et 
al., 1999). Similar studies have also documented evidence indicating that human 
immunodeficiency virus infection have a strong association with abnormal vaginal 
microbiotia particularly, bacterial vaginosis [Taha, 1999]. Studies have also shown that the 
absence or depletion of lactobacilli in the vagina associated with overgrowth of anaerobic 
pathogens causing BV results in significantly increased risk for HIV (as well as gonorrhea, 
chlamydia, and herpes simplex virus infections) [Wiesenfeld, 2003]. By mechanisms yet to 
be elucidated, BV displaces lactobacilli, elevating vaginal pH and creating an environment 
within which the pathogens survive and can infect the host. It is important to note also that 
penile microbiota may contribute significantly to susceptibility to HIV infection. Several 
randomized trials demonstrated decreased risk of trichomoniasis and bacterial vaginosis 
(BV) in the female sexual partners of circumcised men (Gray et al 2009). It is very pertinent 
to better understand the biological mechanisms by which male circumcision reduces the risk 
of HIV infection as this may lead to the development of novel, non-surgical prevention 
strategies. It has been asserted that male and female genital microbial communities may 
play an important role in modulating HIV risk [Galvin & Cohen, 2004]. Genital mucosal 
inflammation induced by microbes leads to the activation of HIV target cells and an increase 
in HIV susceptibility [de Jong & Geijtenbeek, 2009]. The dominant HIV target cells in the 
genital mucosa are two dendritic cell types, langerin+ Langerhans’ cells and DC-SIGN+ 
dendritic cells. The biological mechanism underlying circumcision-conferred protection 
against HIV is likely to be multifactorial. Post- circumcision anatomical, immunological, and 
microbiological changes have all been hypothesized to contribute to the reduction in HIV 
risk. From the anatomical and immunological perspective, the inner surface of the foreskin 
is lightly keratinized and contains abundant Langerhans cells close to the mucosal surface 
resulting in a large number of exposed HIV target cells in the erect uncircumcised penis 
(Patterson et al., 2002; McCoombe & Short, 2006). From a microbiological perspective, the 
intact foreskin may support the survival of genital microbes associated with increased 
foreskin mucosal inflammation and Langerhans’ cell activation. Of note, the protection 
against sexually transmitted infections and BV conferred to the female partners of 
circumcised men [Bailey et al., 2007;Auvert et al., 2005;Gray et al., 2009] strongly suggests 
circumcision-associated microbiological changes in the male genital mucosa. 
In a study that assessed the penile (coronal sulci) microbiota in 12 HIV-negative Ugandan 
men before and after circumcision revealed a total of 42 unique bacterial families in the 
coronal sulci microbiota, with 38 bacterial families among pre-circumci- sion samples versus 
36 detected among post-circumcision samples. Pseudomonadaceae was the most abundant 
family irrespective of circumcision status, constituting over 50% of the coronal sulci 
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microbiota, followed by Clostridiales Family XI, Oxalobacteraceae, and Prevotellaceae for 
pre-circumcision and Corynebacteriaceae, Oxalobacteraceae, and Staphylococcaceae for 
post-circumcision (Price et al 2010). The study suggests that anoxic microenvironment of the 
subpreputial space may support pro-inflammatory anaerobes that can activate Langerhans 
cells to present HIV to CD4 cells in draining lymph nodes. Thus, the reduction in putative 
anaerobic bacteria after circumcision may play a role in protection from HIV and other 
sexually transmitted diseases. 
4. The role of normal vaginal microbiota  
It has been reported previously that more than 60 different bacterial species colonize the 
healthy vagina (Reid et al 1990).  A recent study sampled the vaginal bacterial communities 
of 396 asymptomatic North American women who represented four ethnic groups (White, 
Black, Hispanic and Asian) and the species composition was characterized by pyro-
sequencing of barcoded 16S rRNA genes. The study revealed that the bacterial communities 
clustered into five groups: four were dominated by Lactobacillus iners, L. crispatus, L. gasseri, 
or L. jensenii, whereas the fifth had lower proportions of lactic acid bacteria and higher 
proportions of strictly anaerobic organisms, indicating that a potential key ecological 
function, the production of lactic acid, seems to be conserved in all communities. The 
proportions of each community group varied among the four ethnic groups, and these 
differences were statistically significant (Ravel et al. 2011). This shows that different vaginal 
bacterial ecosystems varies in people but conferring the same protective role as the human 
vaginal microbiota seem to play a key role in preventing a number of urogenital diseases, 
such as bacterial vaginosis, yeast infections, sexually transmitted infections, urinary tract 
infections and HIV infections (Taha, 1999). Studies have shown that urogenital cells are 
covered by dense bacterial biofilms, whose composition changes constantly, but in which 
lactobacilli predominate, at least until menopause. Vaginal lactobacilli have been shown to 
inhibit the growth of Gardnerella vaginalis and mobiluncus in vitro, with the greatest 
inhibition observed in the presence of lactobacilli producing lactic acid. Hydrogen peroxide-
producing lactobacilli have been recovered from the vagina of 96% of 28 non-pregnant 
women without bacterial vaginosis, compared with 6% of 67 women with bacterial 
vaginosis (Eschenbach et al. 1989). The presence of lactobacilli on vaginal epithelial cells 
seems to act, not only as a barrier to infection, by blocking adherence of pathogens, but their 
capability of producing such antibacterial materials as hydrogen peroxide to limit pathogen 
growth, production of biosurfactants that inhibit pathogen adherence, and their ability to 
prime macrophages, leukocytes, cytokines, and other host defenses also contribute to the 
protection of the vagina against uropathogens (Reid, 1999). Full genome sequencing of 
Lactobacillus plantarum KCA1 isolated from the vagina of a healthy Nigerian woman has 
revealed the presence of several novel phage defense genes encoding clustered regularly 
interspaced short pallindromic repeats (CRISPR)-associated proteins and abortive infection 
systems (Anukam et al. 2011). One of the fastest evolving genetic elements in bacterial 
genomes are clustered regularly interspaced short palindromic repeats (CRISPRs) (Sorek et 
al., 2008). CRISPRs have been identified within the genomes of many archaeal and bacterial 
species especially in some vaginal lactobacilli such L. plantarum KCA-1, the only plantarum 
strain know to date with CRISPR. The Spacers are derived from foreign nucleic acids, such 
as those from phage or plasmids and can protect bacteria from subsequent infection by 
homologous phage and plasmids. As a bacterial immune system against foreign DNA, 
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CRISPRs evolve rapidly in response to changing phage pools (Vale & Little, 2010) that is 
usually encountered in the vaginal niche as a result of changes occasioned by the menstrual 
cycle. 
5. The impact of HIV/AIDS in Africa 
Recently, the United Nations AIDS program (UNAIDS) estimated that around 25 million 
people around the world have died from AIDS in the past 30 years since it was recognized, 
and about 40 million more are currently infected with the virus. It is astonishing that 14,000 
new infections occur per day, which means that in every six seconds someone in the world 
will be infected with the HIV virus. Sub-Saharan Africa has been hit hardest by the 
pandemic: about 83% (18.26 million) of AIDS deaths and 71% (28.4million) of HIV infections 
have occurred in this war-ravaged, poverty stricken part of the continent probably due to 
political instability and global climate changes. African region holds just over 10% of the 
world's population, but is home to more than 60% of all people living with HIV and more 
than two-third of all women living with HIV. In some African nations, over 30% of the adult 
population is HIV-positive. (UNAIDS, 2002). In Nigeria, with about 25% of the African 
population, a recent national HIV prevalence sentinel survey by the Federal Ministry of 
health showed that the number of people living with HIV/AIDS in 2009 was between 3.2 
and 3.8 million (Report, 2009). According to the report, the age group 20-24 years had the 
highest national prevalence of 5.6 per cent, and the HIV prevalence for women aged 15-24 
years remains 5.2 per cent. The statistics are very grim all over Africa, in that in 2000, of the 
1.4 million children world-wide living with HIV/AIDS, 1.1 million were in sub-Saharan 
Africa alone (Sengupta and Somini, 2002). By 2002, about 11 million children in Africa had 
lost one or both parents to AIDS. If the disease remains unchecked, the number of African 
children orphaned by AIDS will jump to 20 million by 2010 and most will be old enough to 
watch their parents die from the disease. (Altman and Lawrence, 2002). 
In Africa alone, AIDS has surpassed armed conflict as the leading cause of death (Van 
Niekerk, 2001). With the increasing number of people living and dying of AIDS, only a few 
people have easy access to life-prolonging antiretroviral drug therapy. According to 
UNAIDS, in a press release in July 2, 2002 “In high-income countries, where an estimated 
500,000 people were receiving antiretroviral treatment, 25,000 people died of AIDS in 2001. 
In Africa, however, where only 30,000 of the 28.4 million people infected, were receiving 
antiretroviral treatment, AIDS killed 2.2 million people”. In Nigeria, if not for PEPFAR, the 
situation is harrowing in terms of provision of antiretroviral drugs to people living with 
HIV/AIDS. According to Dr. Peter Piot, executive director of UNAIDS, “The devastating 
impact of HIV/AIDS is rolling back decades of development progress in Africa, and has 
caused economic growth to plummet as much as 4% in sub- Saharan Africa”. HIV/AIDS 
will prevent many sub-Saharan African countries from achieving the Millennium 
Development Goals (MDGs). In high-prevalence countries (those with more than 10% of 
adults infected: Botswana, Lesotho, Malawi, Mozambique, Namibia, South Africa, 
Swaziland, Swaziland, Zambia and Zimbabwe), AIDS is the leading cause of death (MSF, 
2009). 
Over 7,000 women become infected each day. In sub-Saharan Africa, around one quarter of 
females under the age of 30 have HIV and an estimated half billion are at risk of acquiring 
the virus through sexual contact. Although efforts to provide condoms, develop a vaccine, 
use spermicides or anti-retrovirals, have contributed significantly to stem the epidemic due 
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to massive investment by International organizations, such as the Joint United Nations 
Programme on HIV/AIDS (UNAIDS), the Global Fund to Fight AIDS, Tuberculosis and 
Malaria (the Global Fund) and the US President’s Emergency Plan for AIDS Relief 
(PEPFAR). These organizations were formed to specifically address HIV/AIDS. The United 
Nations estimated that at least US $1.5 billion a year could make it possible to achieve 
massively higher levels of implementation of all major components of successful prevention 
programs for the whole of sub-Saharan Africa.  
Having HIV/AIDS is especially devastating among children from the developing countries 
such as sub-Saharan Africa. To comprehend the reality of the vulnerability of children 
affected by the condition, it is important that health care professionals and national policy 
makers understand the global magnitude of the problem. More than 90% of HIV infection 
occurs among the children of southern Africa. Seventy-five percent of those children 
reportedly die before the age of 5 years (DeBaets et al., 2007). Children with HIV/AIDS in 
developing countries continue to be underrepresented among recipients of antiretroviral 
therapy or supportive care, including palliative care (Kline, 2006). A significant number of 
children infected with HIV are also orphans of parents who died of HIV, and they suffer 
from complications including extreme malnutrition. Children who receive professional care 
are often hospitalized for many months at the end of life. The need for prevention and 
alternative management is very obvious 
Meanwhile, more than half of those in need still do not have access to treatment, and 
treatment is posing new challenges for sustainable funding. Most countries with mid to high 
prevalence cannot afford the cost of treatment without international aid; as aid is reduced or 
cancelled, treatment programmes are threatened, drug resistance develops and large 
numbers of people living with HIV may die. In countries like Uganda, patients are being 
turned away from treatment clinics due to lack of resources; 300,000 Ugandans in need of 
treatment are denied their right to health (McNeil, 2010). These numbers will continue to 
grow if both effective prevention and sustainably funded treatment programmes are not 
maintained. Nigeria may not be able to sustain the free anti-retroviral drug program from 
PEPFAR and the future of new infected person may be grim. In 2009, UNAIDS and WHO 
predicted that the $25.1 million needed for HIV/AIDS programmes in 2010 would not be 
forthcoming (UNAIDS, 2009). The total amount of Global Fund grants recommended for 
funding in 2009 was 35% lower than in 2008 (MSF, 2009). 
The programs by all these agencies are planned to cover sexual, mother-to- child and 
transfusion-related HIV transmissions, and would involve approaches ranging from 
awareness campaigns through media to voluntary HIV counseling and testing and the 
promotion and supply of condoms.  
No doubt these programs are laudable, but other alternative measures, such as nutrition 
fortification and probiotics, have not been included as one of the UNAIDS intervention 
programs. Death from AIDS is often precipitated by gastrointestinal infections and diarrhea, 
and indeed, many non-AIDS deaths are due to these infections. It has been estimated that a 
child dies every 15 seconds from diarrheal diseases. While sanitation and early hydration 
based interventions can reduce this death rate, probiotics too could play a role. 
6. Probiotics with clinical evidence against urogenital infections  
During the early periods of probiotics, Scientists paid more attention to gastrointestinal 
effects, but in recent times probiotics are now useful for more than just gastrointestinal 
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health.  In fact, there are specific probiotic products that can help prevent and treat female 
urogenital conditions like bacterial vaginosis, vulvovaginal candidiasis, urinary tract 
infections. It should be noted that the vaginal tract is not internally connected to the 
alimentary canal, however the two are intimately related.  Bacteria that pass through the 
digestive system can ascend via the perineum to the vagina.  So it’s almost a no-brainer to 
expect what promotes gastrointestinal health to have relevance for urogenital health. 
In the late 1980s, human studies were carried out in which L. rhamnosus GR-1 in a douche 
suspension was instilled into the vagina (Bruce and Reid, 1988). This was followed by 
studies using a gelatin capsule containing freeze-dried lactobacilli inserted into the vagina 
(Reid et al 2001). In both cases, the process did not result in any adverse events but did show 
a potential to reduce the risk of recurrence of UTI. The use of orally administered lactobacilli 
was more recently tested, on the basis that if pathogens infect the host from the anal skin, 
why couldn’t lactobacilli also ascend from the anus to the vagina and repopulate the area? 
This concept was verified in several labs (Reid et al, 2001;Antonio et al 2005), and 
Lactobacillus strains GR-1 and RC-14 were shown to reduce UTI, BV and yeast pathogens as 
well as infections (Reid et al 2001; Reid et al. 2003]. The mechanism of action is likely 
multifactorial and could include the ingested lactobacilli ascending from the rectal skin to 
the vagina, or causing a reduced pathogen ascension, or influencing the immune or host 
system in a way that reduces infectivity.  
As this approach to restoration and maintenance of women’s health has become more 
recognized, other groups have undertaken studies using different strains. A prospective 
clinical pilot study was performed to confirm the safety and effectiveness of Lactobacillus 
vaginal suppositories against the recurrence of UTI. The patients enrolled in the study were 
instructed to administer vaginal suppositories containing the strain L. crispatus GAI 98322. A 
significant reduction in the number of recurrences was noted, without any adverse 
complication (P=0.0007). The administration of vaginal suppositories containing L. crispatus 
GAI 98332 seemed to be a safe and promising treatment for the prevention of recurrent UTI 
(Uehara 2006). Delai et al., (2006) demonstrated the effectiveness of the contemporary oral 
administration of L. paracasei subsp paracasei F19 in association with vaginal suppositories 
containing an unnamed L. acidophilus in the treatment of BV. The study had a potentially 
fatal flaw in that not all the 60 subjects had confirmed diagnosis of BV. The subjects were 
randomized in 2 groups: Group A treated with vaginal suppositories containing L. 
acidophilus; Group B treated with the same vaginal suppositories + L. paracasei subsp 
paracasei F 19 for oral administration. There was a significant reduction of vaginal pH, an 
improvement in the amine sniff test and in subjective symptomatology after 3 months of 
treatment and follow-up (3 months). This study needs to be repeated with larger sample 
size, but nevertheless, reviews of the evidence from microbiological and clinical studies 
have indicated that probiotics can be beneficial for preventing recurrent UTI in women in a 
safe manner (Falagas 2006;Reid and Bruce 2006; Hoesl and Altwein 2005). 
The usefulness of orally administered lactobacilli for urogenital health has been 
demonstrated in several other important studies. In a randomized, double-blind, placebo 
controlled trial, 106 women with BV were given a single oral dose of metronidazole (500mg) 
twice daily from days 1-7, plus oral L. rhamnosus GR-1 and L. reuteri RC-14 or placebo twice 
daily from days 1-30. The cure rate in the antibiotic/probiotic group was 88% compared to 
40% in the antibiotic/placebo group (p<0.001). High counts of Lactobacillus sp. 
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(>105CFU/ml) were recovered from the vagina of 96% of probiotic treated subjects 
compared to 53% controls at day 30 (Anukam et al 2006a). In another study using the same 
probiotics, there was a 90% cure of BV following intravaginal administration of the probiotic 
alone, compared to 33% cure with intravaginal metronidazole treatment. In the study, 40 
women diagnosed with BV were randomized to receive either two dried capsules 
containing L. rhamnosus GR-1 and L. reuteri RC-14 each night for five days, or 0.75% 
metronidazole gel, applied vaginally twice a day (in the morning and evening).  Follow-up 
at day 6, 15 and 30 showed cure of BV in significantly more probiotic treated subjects (16, 17 
and 18/20 respectively) compared to metronidazole treatment (9, 9 and 11/20: P= 0.016 at 
day 6, P= 0.002 at day 15 and P= 0.056 at day 30) [Anukam et al 2006b]. This is the first 
proven cure of BV using probiotics and provides hope that alternative remedies to 
antibiotics can be found. 
7. Mechanisms of action 
Probiotics apparently fulfills the definition as "live microorganisms which, when 
administered in adequate amounts, confer a health benefit on the host" through a variety of 
somewhat disparate, somewhat overlapping mechanisms. These include the regulation of 
intestinal microbial homeostasis, the interference with the ability of pathogens to colonize 
and infect the mucosa, the modulation of local and systemic immune responses, the 
stabilization or maintenance of the gastrointestinal barrier function, the inhibition of 
procarcinogenic enzymatic activity and the induction of enzymatic activity that favors good 
nutrition. For example, with respect to epithelial barrier function, probiotics can conceivably 
act through general antimicrobial effects, effects on intestinal permeability in the absence of 
invasive bacteria, effects on epithelial cell inflammatory responses and effects on epithelial 
cell survival. One important effect of probiotics on barrier function is the ability of 
commensal organisms to act through Toll-like Receptors (TLR) on epithelial cells (such as 
TLR2 and TLR4). In particular, it has been shown that such interactions induce the 
production of protective cytokines such as IL-6 that mediate epithelial cell regeneration and 
inhibit epithelial cell apoptosis in the face of agents that otherwise result in epithelial cell 
ulceration (Rakoff-Nahoum et al., 2004). It should be noted, however, that probiotics do not 
affect expression of all TLRs in the same manner. Thus, as shown by Ewaschuk et al., (2007) 
whereas exposure of HT-29 epithelial cells to DNA from pathogenic organisms resulted in 
increased TLR9 expression, exposure to a probiotic did not have this effect. This is in 
keeping with the lesser ability of commensal organisms to induce TLR expression as 
compared with pathogenic organisms. Probiotics may also have effects on epithelial barrier 
function via cellular mechanisms that have little to do with TLR signaling. Thus, in a study 
by Zyrek et al., (2007) it was shown that the probiotic, E. coli Nissle 1917 (EcN) counteracts 
the disruptive effects of enteropathic E. coli (EPEC) on T-84 epithelial cell monolayers by 
altering protein kinase C signaling and causing the redistribution and increased expression 
of zonula-occludens-2 (ZO-2), an important factor in maintaining epithelial tight junction 
function. Along similar lines, Yan et al., (2007) showed that proteins isolated from broths of 
the probiotic Lactobacillus rhamnosus activated mouse epithelial cell Akt and inhibited TNF-
α-mediated apoptosis and promoted growth of both human and mouse colon epithelial cells 
or cultured mouse colon explants. 
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Production of antimicrobial substances, such as organic acids or bacteriocins 
Upregulate immune response (eg, secretory IgA) to possible pathogens or to vaccines 
Downregulate inflammatory response 
Assist in early programming of the immune system to result in a better balanced immune 
response and reducing risk of development of allergy 
Improvement of gut mucosal barrier function 
Enhance stability or promote recovery of commensal microbiota when perturbed 
Modulate host gene expression 
Deliver functional proteins (eg, lactase) or enzymes (natural and cloned) 
Decrease pathogen adhesion 
Table 1. Some proposed probiotics mechanisms of actions  
From the accumulated information on the relation of regulatory T cells and their associated 
cytokines to the function of probiotics, it can be said with some certainty that probiotic 
administration does lead to the increased elaboration of regulatory cytokines and these 
cytokines play a major role in the protective effect of the probiotics. It seems likely that 
probiotics bring about these effects via their interactions with mucosal dendritic cells which 
then produce regulatory cytokines themselves or induce T cells with these properties. There 
is the possibility that probiotics act through the induction of regulatory T cells that suppress 
inflammation-inducing effector cells. This emphasis is based on a rising tide of evidence that 
probiotics have properties that allow them to interact with the mucosal immune system that 
does not arouse an inflammation inducing innate response and the consequent induction of 
master inflammatory cytokines such as IL-12. For example human circulating dendritic cells 
or lamina propria mononuclear cell populations were cultured with cell wall preparations 
from each of the probiotic species in VSL#3 and then assessed cytokine production. It was 
found that bifidobacteria components were generally the most potent in up-regulating IL-10 
by both CD11+ and CD11− dendritic cells whereas components of all VSL#3 strains 
decreased IL-12 production (Mohamadzadeh et al., 2005). While studies on vaginal 
lactobacilli with respect to their probiotic potential are increasing, significant basic research 
studies have only been performed on strains GR-1 and RC-14, particularly looking at modes 
of action. It is clear that these organisms are multifunctional and may affect each host 
differently. The GR-1 strain does not produce hydrogen peroxide but does produce anti-
candida activity as well as bacteriocins and other components, including AI-2 inducers that 
influence the growth and biofilm development of uropathogens. The organism can down-
regulate inflammatory processes, using IL-10 dependent and independent pathways, as 
shown in macrophages studies (Kim et al. 2006). A human genome array study has shown 
that a single intravaginal insertion of Lactobacillus GR-1 can up-regulate host defense 
factors known to be important in fighting infection (Kirjavainen et al., 2008 ). Meanwhile, 
studies with Lactobacillus RC-14 strain have shown that it can up-regulate mucin 
production which may act as a barrier to infection (unpublished data), and down-regulate 
virulence factor expression in pathogens such as staphylococci [Laughton et al 2006]. The 
organism also affects cell membrane components in E. coli and produces biosurfactants that 
inhibit their adhesion to surfaces. 
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8. The rationale for the use probiotics in reducing the risk associated with 
HIV 
Tremendous efforts are being made to develop effective microbicides for the prevention of 
HIV-1 sexual transmission and in clear terms it should represents a primary goal for the 
control of AIDS epidemics worldwide. A promising strategy is the use of bacteria belonging 
to the vaginal microbiota as live microbicides for the topical production of HIV-1 inhibitors. 
A recent review has chronicled the potentials of probiotics to prevent HIV (Bolton et al., 
2008) and some of the points are lighted in line with the objectives of this section. A study 
engineered a human vaginal isolate of Lactobacillus jensenii to secrete the anti-HIV-1 
chemokine RANTES, as well as C1C5 RANTES, a mutated analogue that acts as a CCR5 
antagonist and therefore is devoid of proinflammatory activity. Full-length wild-type 
RANTES and C1C5 RANTES secreted by L. jensenii were purified to homogeneity and 
shown to adopt a correctly folded conformation. Both RANTES variants were shown to 
inhibit HIV-1 infection in CD4 T cells and macrophages, displaying strong activity against 
HIV-1 isolates of different genetic subtypes. The work provides proof of principle for the use 
of some Lactobacilli, notably L. jensenii-produced C1C5 RANTES to block HIV-1 infection of 
CD4 T cells and macrophages, setting the basis for the development of a live anti-HIV-1 
microbicide targeting CCR5 in an antagonistic manner [Luca et al 2010] 
Other studies have previously used Lactobacilli and other probiotic genetically modified 
bacteria to produce specific HIV inhibitory proteins, both membrane-bound and secreted. A 
strain of L. jensenii was engineered to produce functional CD4, the primary receptor for HIV 
[Chang et al, 2003]. There are several classes of proteins that bind to the mannose residues of 
HIV, including a unique 11 kd protein from cyanobacteria (Nostoc ellipsosporum) called 
cyanovirin-N and mannose-binding lectins which also bind to Neisseria gonorrhoeae [Botos & 
Wlodawer, 2005 ].The human commensal bacterium Streptococcus gordonii, L. lactis, L. 
plantarum, and L. jensenii have been genetically engineered to express functional, HIV-
binding cyanovirin-N [Pusch et al 2005; Liu et al 2006].An E. coli strain which colonizes the 
colon and rectum, and may thus potentially prevent anal transmission, has been modified to 
secrete peptides hybridized with hemolysin A, a protein that can complex with the HIV 
fusion protein gp41 [Rao et al 2005]. FI-1, FI-2, and FI-3 are also peptides that can interfere 
with gp41 and were cloned into L. plantarum and L. gasseri [Pusch et al 2006]. L. reuteri RC-
14, which has been studied as a potential probiotic, was modified to produce 3 HIV entry 
and fusion inhibitors: CD4D1D2IgKLC, MIP-1฀, and T-1249 [Liu et al 2006] Antibody to the 
cellular adhesion molecule intercellular adhesion molecule has been shown to inhibit cell-
mediated trans- epithelial HIV-1 transmission in vitro and was functionally excreted by a 
bioengineered strain of L. casei [Chancey et al 2006]. Some of these products have been used 
in rodent models, but none has been tested in humans. 
By their production of lactic acid, lactobacilli may help maintain a low vaginal pH that can 
inhibit other bacteria and viruses. Among postmenopausal women receiving estrogen 
replacement therapy, those who were lactobacilli-positive had low pH 4.4 compared with 
the lactobacilli-negative women pH 5.2 (Ginkel et al 1993). In 55 menarchal women, 
colonization with hemolytic streptococci, G. vaginalis, or mixed organisms was associated 
with higher vaginal pH than colonization with normal microbiota and yeast (Caillouette et 
al. 1997).  As previously mentioned, BV is associated with a lack of hydrogen peroxide-
producing lactobacilli. Colonization with hydrogen peroxide producers is associated with 
lower frequency of gonorrhea (Antonio et al 1999). Compared with women colonized with 
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hydrogen peroxide-producing lactobacilli, women colonized with hydrogen peroxide 
nonproducers or without lactobacilli had unadjusted odds ratios of HSV-2 seroconversion of 
2.4 and 2.6, respectively (Cherpes et al 2003). The difference in seroconversion rates may be 
due to a direct antiviral effect of hydrogen peroxide or due to an increased risk of HSV 
infection in women with BV. 
Several mammalian peroxidases, including myeloperoxidase, eosinophil peroxidase, and 
lactoperoxidase can combine with hydrogen peroxide and a halide (chloride, iodide, 
bromide, thiocyanate) to form “a powerful antimicrobial system” effective against many 
pathogens (Klebanoff et al 1991). Lactobacilli, streptococci, and pneumococci can release 
hydrogen peroxide and in vitro, in mixed cultures, their toxicity against other bacteria, 
fungi, viruses, spermatozoa, and tumor cells can be boosted by addition of a peroxidase and 
a halide. This system was found to inhibit cell-free HIV replication in culture in the presence 
of hydrogen peroxide-producing, but not nonproducing, lactobacilli (Klebanoff et al 1991a, 
Klebanoff et al 1991b). L. crispatus and L. jensenii inhibit gonococci at both acidic and neutral 
pH. This inhibition is susceptible to bovine catalase, suggesting that hydrogen peroxide is 
the primary mediator (St Amant et al 2002).  Lactobacilli have been found to produce many 
other bacteriocins, enzymes, and antimicrobial peptides that may make them more 
competitive in the vaginal microbiota (Silva et al 1987;Naidu et al 1999). 
Another potentially beneficial characteristic of probiotic bacteria studied in the 
gastrointestinal tract is their pleomorphic effect on host mucosal immunity that could affect 
the vaginal mucosa’s defense against HIV and other STIs or resistance to BV (Sheih et al 
2001). Evidence for enhancement of humoral responses to rotavirus and Salmonella typhi has 
been shown through IgA levels in probiotic treated children and adults (Kaila et al., 1992). 
Animal and human data suggest that probiotic use is associated with induction of innate 
and cell-mediated immune responses (Cross 2002), including increased macrophage 
phagocytic activity (Miettinen et al 2000), complement and reticuloendothelial activation 
(Gill et al 2000), stimulation of interferon-gamma, interleukin (IL)-12, and IL-18 (Hessle et 
al., 1999) and increased natural killer cell activity (Matsuzaki and Chin, 2000). However, the 
major cell wall component of lactobacilli, muramyldipeptide, can be pyrogenic, and there is 
concern that lactobacillus enhancement of the T-helper-1 proinflammatory pathway could 
have negative health consequences (Perdigon and Holgado, 2000). Also, there is concern 
that the dosage and duration of therapy must be considered so as to optimally enhance and 
not suppress immunity (Perdigon et al., 1991). Fortunately, probiotic strains have not been 
found to cause a systemic antibody response (Sheen et al 1995). 
Modification of intestinal mucosal immunity by orally administered probiotics may also 
affect vaginal mucosal immunity to specific pathogens (de Vrese and Schrezenmeir, 2002). 
In fact, genetic engineering of probiotic bacteria to express pathogen antigens and serve as 
oral vaccines is being explored (Reveneau et al 2002). In other mucosal vaccine trials, 
introduction of antigens from HPV and HIV has been accomplished in S. gordonii (an oral 
commensal) and L. casei. Local and systemic immune responses were detected in BALB/c 
mice and Cynomolgus monkeys after vaginal colonization with these strains (Medaglini, 
1998). However, there is not yet a good understanding of the relationship between mucosal 
immunity and BV. In a study of adolescents, BV was found to be inversely associated with 
lactobacilli counts but was independent of lactobacilli-specific immune responses in isolated 
peripheral blood leucocytes, and independent of local immune responses measured by 
antibodies and cytokines measured in cervicovaginal lavages (Alvarez-Olmos et al 2004). In 
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a study of pregnant women, carriage of a variant of the toll-like receptor-4 gene compared 
with carriage of the dominant genotype was associated with higher vaginal pH and a 10-
fold increase in vaginal G. vaginalis levels. Colonization with G. vaginalis or anaerobic Gram-
negative rods in the dominant allele carriers was associated with elevated vaginal IL-1 and 
IL-1ra but not in the variant homozygotes (Genc 2004). Probiotic modulation of mucosal 
immunity may help prevent BV and other STIs including HIV, but it is difficult to predict 
which strains might do this without knowing the immune correlates of protection and how 
specific strains will affect these factors. More studies are needed in these areas of scientific 
enquiry. 
9. Some clinical evidence of probiotics in helping to reduce the impact of 
HIV/AIDS 
The increased searchlight on HIV/AIDS care in Africa has been rekindled following 
financial donations from spirited organizations and individuals on increasing access to 
antiretroviral (ARV) medication. Nevertheless this is cardinal, efforts are also needed to 
provide safe and affordable interventions for those without access to ARVs or with CD4 
counts too high to initiate ARV therapy, yet whose quality of life is diminished by 
micronutrient deficiencies, gut infections such as diarrhea, and other complicated conditions 
associated with HIV infection. The use of micronutrients, most notably vitamin B-complex 
in combination with C and E, appears to be an effective intervention that have been 
associated with reduced mortality and in most cases it results in increasing the CD4 counts 
of the infected person.(Kanter et al., 1991; Kaiser et al., 2006;Jiamton et al., 2003) The 
WHO/FAO has recommended that an ‘‘increased micronutrient intake can be best achieved 
through an adequate diet,’’(WHO, 2003) favoring food-based interventions. 
It should be noted that the gastrointestinal tract is one of the most severely affected organ by 
HIV (Kotler et al., 1984;Sharpstone et al., 1999). Inflammation results in damage to the 
epithelial barrier, leading to an increased leakage of microbial products into the 
bloodstream. Recently, it was theorized that this may be an ongoing source of systematic 
immune activation that fuels HIV (Brenchley, 2006) although this association was less clear 
in an African population (Redd et al., 2009). Capsule proteins of HIV may further facilitate 
viral replication by eliciting a profound Th-2 activation that inhibits an effective immune 
response against the virus (Kanter et al., 1991). 
Probiotic bacteria can potentially restore an effective gut barrier (Luyer et al., 2005;Yan et al., 
2007) thereby reducing systemic immune activation. Furthermore, probiotics have been shown 
to upregulate T-regulatory lymphocytes (Baroja et al., 2007;Foligne et al., 2008) potentially 
skewing the immune system away from a Th-2-dominant state (Mohamadzadeh et al., 2005). 
Probiotic usage has been shown to be safe among people living with HIV (Wolf et al., 
1998;Salminen et al., 2004) and recent randomized trials in Brazil (Trois et al., 2008) and 
Nigeria (Anukam et al., 2006) suggest that probiotic use can increase the CD4 count. In the 
Nigerian study, conventional yogurt fermented with Lactobacillus delbruekii var bulgaricus 
and Streptococcus thermophilus was supplemented with probiotic Lactobacillus rhamnosus 
GR-1 and L. reuteri RC-14. Twenty-four HIV/AIDS adult female patients (18 to 44years) with 
clinical signs of moderate diarrhea, CD4 counts over 200, and not receiving antiretrovirals or 
dietary supplements, consumed either 100 mL supplemented or unsupplemented yogurt per 
day for 15 days. Hematologic profiles, CD4 cell counts, and quality of life was evaluated at 
baseline, 15 and 30 days postprobiotic-yogurt feeding. There was no significant alteration in 
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the hematologic parameters of both groups before and after the probiotic-yogurt feeding, with 
the probiotic yogurt group at baseline, 15 and 30 days had a mean WBC count of 5.8 ± 0.76 
X109/L, 6.0 ± 1.02 X109/L, and 5.4 ± 0.14 X109/L, respectively. However, the mean CD4 
cell count remained the same or increased at 15 and 30 days in 11/12 probiotic-treated subjects 
compared to 3/12 in the control. Diarrhea, flatulence, and nausea resolved in 12/12 probiotic- 
treated subjects within 2 days, compared to 2/12 receiving yogurt for 15 days. This is the first 
study to show the benefits of probiotic yogurt on quality of life of women in Nigeria with 
HIV/AIDS, and suggests that perhaps a simple fermented food can provide some relief in the 
management of the AIDS epidemic in Africa. 
The most commonly used vehicle for supplying probiotics; yogurt, is a significant source of 
vitamin A, B-complex, zinc, and high-biologic-quality protein (Sattler et al., 2008) and is 
therefore, an excellent food-based intervention to improve micronutrient intake among 
people living with HIV/AIDS. On the basis of these notions, a community kitchen in 
Mwanza, Tanzania, was established in 2004 to produce yogurt supplemented with 
Lactobacillus rhamnosus GR-1 (Fiti) to be distributed as an adjunct to the diet of people 
living with HIV. Irvine et al., (2010) carried out an observational retrospective study over a 
period of 3 years, with longitudinal comparison of the CD4 count within participants (n=68) 
before and during probiotic yogurt consumption, and compared with a control group of 
participants not consuming the yogurt (n=82). Among the yogurt consumers before use and 
the nonconsumers, an average increase in CD4 count was seen of 0.13 cells/mL/day (95% 
CI; 0.07-0.20, P=<0.001). After commencing consumption, yogurt consumers experienced an 
additional increase of 0.28 cells/mL/day (95% CI; 0.10-0.46, P=0.003). When adjusting for 
length of time using antiretroviral medication, the additional increase explained by yogurt 
consumption remained 0.17cells/mL/day (95% CI; 0.01-0.34, P=0.04). Treatment with 
antiretroviral medication was associated with an increase of 0.27 cells/mL/day (95% CI; 
0.17-0.38, P=<0.001). The study concluded that introduction of probiotic yogurt, made by 
local women in a low-income community in Tanzania, was significantly associated with an 
increase in CD4 count among consumers living with HIV. Another similar study assessed 
among women with HIV, whether long-term oral Lactobacillus rhamnosus GR-1 and 
Lactobacillus reuteri RC-14 supplementation can prevent bacterial vaginosis (BV) and 
enhance the cure rate of metronidazole among those with BV. It involved a randomized, 
double-blind, placebo-controlled trial conducted among 65 HIV-infected women with an 
aberrant microbiota (Nugent score 4–10) were selected to receive daily probiotics or placebo 
for 6 months. Those with BV (Nugent score 7–10) additionally received metronidazole for 10 
days (400 mg twice daily). Although there was no enhanced cure rate of BV among women 
with HIV treated with adjuvant probiotics to metronidazole treatment. However, among 
women with an intermediate vaginal flora, probiotics tended to increase the probability of a 
normal vaginal flora (odds ratio 2.4; P=0.1) and significantly increased the probability of a 
beneficial vaginal pH (odds ratio 3.8; P=0.02) at follow-up (Hummelen et al., 2010) 
10. Beware of some probiotic claims 
While we suggest the potential use of probiotics may be important in ameliorating the 
impact of urogenital infections in Africa, however there must be caution in terms of 
controlling the importation of probiotic products. National agencies in Africa in charge of 
natural products should be prepared to know the probiotic products there are really called 
probiotics. There are numerous probiotic claims over the internet which may mislead people 
in buying useless products. 
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A number of so-called probiotic products claim to be useful for UTI management. Sadly, their 
marketing hype is not supported by properly performed human studies. US based Natren, 
makers of probiotic face cream, claim that oral and vaginal GyNaTren helps ‘balance the 
intestinal and vaginal ecology’ and should be used to treat vaginitis. No peer-reviewed studies 
validate this claim. Other products available in Europe, namely Lactovaginal, Gynoflor, 
Fermalac, Florgynal, Ecovag, Culturelle VC, SymbioFem Plus and Yeast- guard all suffer from 
lack of appropriate clinical sub- stantiation, and cannot be recommended to prevent UTI. 
Clearly, companies marketing such products have an obligation to provide evidence of clinical 
efficacy. This is predicated on the fact that some products may contain different genera, 
different species, or even different strains of the same species, and not all products should be 
expected to work the same. Therefore, claims of efficacy should be target specific and should 
be made only for products that have been found efficacious in carefully designed studies. The 
marketplace has many examples of different strains of the same species: Lactobacillus 
acidophilus NCFM and La-1; L. rhamnosus GR-1 and L. rhamnosus GG; Lactobacillus casei 
Shirota and DN-114 001; Lactobacillus reuteri RC-14 and ATCC 55730; and Bifidobacterium 
lactis HN019 and BB-12; Lactobacillus plantarum WCFS1, Lactobacillus plantarum KCA-1. Each of 
these strains has a unique dossier to document individual health benefits. It is noteworthy, 
however, that among dozens of European commercial products, the same biotype (based on 
pulsed-field gel electrophoresis of chromosomal DNA) was predominant among 
Bifidobacterium- containing products (Masco et al., 2005), suggesting that Bifidobacterium 
strains used commercially may not be so diverse. The fact that consumers buy such products 
suggests that the current management of urogenital infections is not sufficiently well handled 
by the sole use of antimicrobials. In addition, patients, particularly those suffering from 
recurrent infections, are well aware of the side effects of antibiotic therapy and the ever-
increasing problem of bacterial resistance. 
11. Can the use of probiotics make an impact in Africa? 
The presence of bacterial vaginosis-causing organisms that are perhaps more prevalent in 
Africa provokes the loss of normal vaginal bacterial flora, and causes vaginal inflammation 
and increased pH levels. The resulting altered vaginal environment increases the risk of 
transmission of HIV. In addition diarrhoeal diseases, HIV/AIDS complications, and other 
infectious diseases are major contributors to morbidity and mortality in sub-Saharan Africa. 
Morbidity from these illnesses causes economic hardship and mortality results in the loss of 
the next generation and destruction of the present adult leadership. Several studies have 
pointed out that the use of probiotics can significantly improve the wellbeing of individuals 
infected with HIV/AIDS (Anukam, 2007). For example, studies conducted in Africa have 
estimated the average annual increase in CD4 count of 90cells/mL with ARV treatment 
(Lawn et al., 2006) and an average decline of 20 to 50 cells/mL/year without ARV treatment 
(Holmes et al., 2006;Urassa et al., 2004). In the Tanzanian study, (Irvine et al., 2010), a similar 
rate of increase was observed of 99 cells/mL with ARV treatment (0.27 cells/mL/d), 
whereas no significant decrease was observed without ARV treatment. The results of this 
study indicate that probiotic yogurt consumption is associated with an overall increase in 
CD4 count of 62 cells/mL/year (0.17 cells/mL/d). This could be due to an accelerated 
immune reconstitution after initiation of ARV treatment, thus shortening the time of severe 
immune deficiency, or may be due to an increase in CD4 count among those not yet eligible 
for ARV treatment, which may potentially delay the need for ARV medication. However, 
this study is yet to be replicated in other African sites with similar burden of HIV infections. 
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Indication  Probiotic Genus, 
Species and 
Strain 

















Florastor (powder) www.florastor.com Lalflor 
(capsule) www.institut-rosell.com 
L rhamnosus GG Culturelle (capsule) www.culturelle.com Danimals 
(drinkable yogurt) www.danimals.com 
L casei DN114001 DanActive (fermented milk) www.danactive.com 
L acidophilus
CL1285 plus L 
casei 
BioKCL1285 (fermented milk, capsule) 
www.biokplus.com 
Gut transit time B animalis DN173 
010 (Bifidus 
regularis) 
Activia (yogurt) www.activia.com 
Infant diarrhea L rhamnosus GG 
(LGG) 
Culturelle (capsule) www.culturelle.com Danimals 
(drinkable yogurt) www.danimals.com 
L casei DN114001 
(Immunitas) 











strains and S. 
thermophilus 
VSL#3 (powder) www.vsl3.com 
Keeping healthy L reuteri ATCC 
55730 
BioGaia Chewable Gut Health Tablets, BioGaia Gut 
Health Probiotic Straws, www.everidis.com 
Lactose 
intolerance 
Most strains L 
bulgaricus and/or 
S thermophilus 
All yogurts with live, active cultures 
Immune support B lactis HN019 
(HOWARU or 
DR10) 
Strain sold as an ingredient for dairy and 
supplement products—contact Danisco 
www.danisco.com 
B lactis Bb-12 Good Start Natural Cultures (infant formula) 
www.verybestbaby.com/GoodStart/Overview.aspx 
Yo-Plus (yogurt) www.yo-plus.com 
L casei DN114001 DanActive (fermented milk) www.danactive.com 
Table 2. Some probiotic products with published clinical studies 
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12. Conclusions 
Several studies have shown that probiotics could enhance the health and well-being of 
individuals in sub-Saharan Africa, but sadly the use of probiotics has not become popular 
for several reasons outlined by Anukam and Reid (2005). First, pharmaceutical companies 
that manufacture probiotics would be forced to lower prices, which would adversely affect 
their revenues. Secondly, storage and distribution problems make the allocation of 
probiotics difficult. Dairy versions of probiotics require refrigeration, and other forms 
incorporated in tablets, capsules, and powders must be retained in proper vials with 
appropriate dessicants. Accordingly, storage and distribution issues present major 
challenges to the effective implementation of probiotic treatment since domestic technology 
is frequently insufficient for proper maintenance. Finally, cultural acceptance presents a 
major challenge for probiotic use. For example, if local customs call for a diet free of dairy 
products, it could be difficult to convince these people to consume a fermented milk drink.  
The lack of any probiotic fermented food products in Africa at present, with the exception of 
a grass roots community kitchen in Tanzania where probiotic Lactobacillus rhamnosus GR-1 is 
used (www.westernheadseast.ca), makes it difficult to perform studies and provide benefits 
to the population. Until this happens, hopefully with clinically proven products and not 
simply ones where the term probiotic is used or bacteria are added as an ingredient without 
testing, indigenous fermented foods may be explored further as a source of health benefits.  
While many fermented foods are eaten in Africa soon after being produced, the lack of 
refrigerated distribution networks makes it difficult to reach a large population. In this 
context, McMaster et al., (2005), developed a microencapsulation delivery system for 
Bifidobacterium lactis DSM 10140, which if successfully applied to foods might overcome 
some of the shelf-life problems faced by lack of refrigeration. The study used two existing 
traditional fermented foods, ‘‘amasi’’ and ‘‘mahewu.’’ The gellan/xanthan microcapsules 
containing viable B. lactis were tested under simulated physiological conditions and added 
to pasteurized beverages. The results showed protection of the organism in low pH and 
against the biocidal activity of pancreatic and bile acids. For ‘‘mahewu,’’ microencapsulation 
of B. lactis with storage aerobically at 4oC and 22oC enhanced survival over a 21-day period 
compared to free cells. This is still not reflective of extreme temperatures found in Africa, so 
further studies are needed to confirm if this method will lead to making ‘mahewu’ available 
to people.  
In confirming the validity of evidence on probiotics, the United Nations Food and 
Agriculture Organization and the World Health Organization (WHO/FAO, 2001) sponsored 
an Expert Consultation in 2001. The resulting Report stressed that “Efforts should be made 
to make probiotic products more widely available, especially for relief work and 
populations at high risk of morbidity and mortality”. Eleven years later, this clarion call to 
the healthcare community and to the food industries in providing probiotics to the people of 
sub-Saharan Africa has yet to be answered. 
With the increasing number of people living and dying of AIDS, only a few people have 
easy access to life-prolonging antiretroviral drug therapy. The HIV/AIDS pandemic is 
propelled by social, cultural and economic gender inequalities that limit children and 
women’s ability to protect themselves from infection. The main strategies by UNAIDS for 
HIV prevention are promotion of condoms, reducing the number of sexual partners, and 
treatment of reproductive tract infections. These strategies are laudable but not feasible for 
many women. Occasionally, it may seem appropriate to provide perspective and to 
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verbalize concerns and disquietude anytime the UN publishes the life expectancy of the 
people from developing countries. No one has taken the pain to ask the question why the 
Japanese, coincidently with a long history of probiotic consumption, have the highest life 
expectancy in the world today and low HIV prevalence (<0.1%, contributed through 
contaminated blood products) (Oelrichs, 2004), while the people from sub-Saharan Africa, 
coincidently with no classically defined probiotic consumption, have the lowest life 
expectancy in the world, and the highest HIV prevalence. Besides, there are no available 
probiotics to boost the immune system (Gill et al., 2002), treat diarrhea and prevent 
urogenital infections.   
More studies and interest are needed to expand our understanding of this approach to 
healthcare in sub-Saharan Africa, to knowing their limitations and understanding their 
mechanisms of action, and examining economic, social, political and behavioral changes for 
more expansive introduction of probiotic concepts. Hopefully, concerted research efforts 
will stimulate other scientists, students, and physicians to explore this area. The 
development of recombinant strains expressing potent anti-HIV microbicides may provide a 
more specific preventive approach in future years. 
Making probiotic products available to both the uninfected and infected persons, gives them 
opportunity to choose among other health promoting products. Probiotics may be a viable 
paradigm towards reducing the risk associated with acquisition of HIV mostly in women by 
restoring the vaginal microbiota and help relieve the suffering of AIDS patients, most of 
who suffer from chronic diarrhea. 
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